Ligand Pharmaceuticals Inc (LGND)
73.90
+1.58
(+2.18%)
USD |
NASDAQ |
May 03, 16:00
73.90
0.00 (0.00%)
After-Hours: 20:00
Ligand Pharmaceuticals Research and Development Expense (Quarterly): 5.488M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.488M |
| September 30, 2023 | 5.532M |
| June 30, 2023 | 6.854M |
| March 31, 2023 | 6.663M |
| December 31, 2022 | 9.197M |
| September 30, 2022 | 9.239M |
| June 30, 2022 | 8.467M |
| March 31, 2022 | 9.179M |
| December 31, 2021 | -18.66M |
| September 30, 2021 | 16.94M |
| June 30, 2021 | 15.95M |
| March 31, 2021 | 17.88M |
| December 31, 2020 | 3.027M |
| September 30, 2020 | 12.85M |
| June 30, 2020 | 12.73M |
| March 31, 2020 | 11.89M |
| December 31, 2019 | 18.66M |
| September 30, 2019 | 13.74M |
| June 30, 2019 | 12.21M |
| March 31, 2019 | 11.29M |
| December 31, 2018 | 8.84M |
| September 30, 2018 | 5.483M |
| June 30, 2018 | 6.135M |
| March 31, 2018 | 7.407M |
| December 31, 2017 | 8.633M |
| Date | Value |
|---|---|
| September 30, 2017 | 4.759M |
| June 30, 2017 | 4.822M |
| March 31, 2017 | 8.673M |
| December 31, 2016 | 6.408M |
| September 30, 2016 | 5.898M |
| June 30, 2016 | 4.914M |
| March 31, 2016 | 4.004M |
| December 31, 2015 | 2.275M |
| September 30, 2015 | 1.945M |
| June 30, 2015 | 3.416M |
| March 31, 2015 | 3.368M |
| December 31, 2014 | 0.905M |
| September 30, 2014 | 3.021M |
| June 30, 2014 | 2.689M |
| March 31, 2014 | 3.131M |
| December 31, 2013 | 2.374M |
| September 30, 2013 | 2.414M |
| June 30, 2013 | 2.022M |
| March 31, 2013 | 2.465M |
| December 31, 2012 | 2.475M |
| September 30, 2012 | 2.647M |
| June 30, 2012 | 2.85M |
| March 31, 2012 | 2.817M |
| December 31, 2011 | 2.598M |
| September 30, 2011 | 2.471M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-18.66M
Minimum
Dec 2021
18.66M
Maximum
Dec 2019
9.360M
Average
9.239M
Median
Sep 2022
Research and Development Expense (Quarterly) Benchmarks
| ANI Pharmaceuticals Inc | 9.867M |
| ADMA Biologics Inc | 0.4455M |
| Viking Therapeutics Inc | 24.10M |
| Voyager Therapeutics Inc | 25.76M |
| Palatin Technologies Inc | 5.554M |